Anzeige
Mehr »
Login
Donnerstag, 06.03.2025 Börsentäglich über 12.000 News von 689 internationalen Medien
Wie KI die Medikamentenzulassung um Jahre verkürzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40NG9 | ISIN: US83548R4020 | Ticker-Symbol: H3D0
NASDAQ
05.03.25
21:37 Uhr
1,510 US-Dollar
0,000
0,00 %
1-Jahres-Chart
SONNET BIOTHERAPEUTICS HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
SONNET BIOTHERAPEUTICS HOLDINGS INC 5-Tage-Chart

Aktuelle News zur SONNET BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
26.02.Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors4
26.02.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report1
19.02.Sonnet BioTherapeutics advances novel ADC platform1
19.02.Sonnet BioTherapeutics macht Fortschritte bei neuartiger ADC-Plattform1
19.02.Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline ...49Building on proven targeting of the FHAB domain, Sonnet's ADC platform offers flexible payload capacity and controllable drug-antibody ratios (DAR) An epidermal growth factor receptor 2 (HER2) ADC...
► Artikel lesen
13.02.Sonnet BioTherapeutics Holdings, Inc. - 10-Q, Quarterly Report2
13.02.Sonnet BioTherapeutics reports wider Q1 net loss, CFO transition2
SONNET BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
13.02.Sonnet BioTherapeutics ernennt neuen Chief Business Officer1
13.02.Sonnet BioTherapeutics GAAP EPS of -$1.561
13.02.Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update107Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of dosing was seen in 48% evaluable monotherapy patients,...
► Artikel lesen
13.02.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report-
30.01.Sonnet BioTherapeutics Holdings, Inc. - S-1/A, General form for registration of securities8
29.01.Sonnet BioTherapeutics secures EU patent for FHAB technology2
28.01.Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB Platform Technology99European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company's Fully Human Albumin Binding (FHAB®) domain fusion proteins In addition to the U.S. and EU, Sonnet's global IP...
► Artikel lesen
28.01.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report1
22.01.Sonnet BioTherapeutics Holdings, Inc. - S-1, General form for registration of securities1
22.01.Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar3
21.01.Sonnet BioTherapeutics startet Studie mit Kombination aus SON-1010 und Trabectedin3
21.01.Sonnet BioTherapeutics begins trial combining SON-1010, trabectedin2
21.01.Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas160SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin (Yondelis®) with...
► Artikel lesen
Seite:  Weiter >>
80 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1